🚨 Eli Lilly slips as generic weight-loss drugs flood India; Novo Nordisk holds firm #EliLilly #NovoNordisk #WeightLossDrugs

Wegovy High-Dose Priced $50 Below Zepbound Novo Nordisk priced high-dose Wegovy $50 below Eli Lilly's Zepbound on Apr 8, 2026; the pricing move will influence payer negotiations and formulary placement in the GLP-1 class.

Wegovy High-Dose Priced $50 Below Zepbound: Novo Nordisk priced high-dose Wegovy $50 below Eli Lilly's Zepbound on Apr 8, 2026; the pricing move will influence payer negotiations and formulary placement in the GLP-1 class. 👈 Read full analysis #Wegovy #Zepbound #NovoNordisk #ELiLilly #GLP1

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment - Replaye CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
replaye.com/novo-nordisk...

#News #NovoNordisk #Wegovy #GLP1 #WeightLoss

La diabetes tipo 2, una enfermedad que “no es solo azúcar”: “Un mal control puede afectar a múltiples sistemas” El control del azúcar es solo la punta del iceberg de una enfermedad muy compleja, que afecta a muchas partes del cuerpo y puede derivar en serias complicaciones

#Profesionales | 🔹La #DiabetesTipo2 va más allá del azúcar. El Dr. Cornejo destaca un enfoque integral en El Gran Evento de #NovoNordisk

Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

#EliLilly has claimed US approval for oral GLP-1 agonist #orforglipron (under the name #Foundayo) setting up a market clash with #NovoNordisk 's first-to-market #Wegovy pill.

Pharmalittle: We're reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more The FDA is moving toward allowing compounding pharmacies to produce injectable peptides that were banned over significant safety concerns

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more news.. statnews.com/pharmalot/20... #pharma #FDA #compounding #Iran #obesity #Amgen #Bayer #NovoNordisk

Novo hits back at rivals with cut-price Wegovy subscriptions Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.

Trying to claw back market share in the #weightloss category, #NovoNordisk has launched a #subscription-based service for #cashpayers that offers #Wegovy at a "lower, predictable #monthlyprice."

pharmaphorum.com/news/novo-hi...

Novo Nordisk shares have risen following a recommendation for the drug Wegovy by Britain's drug price regulator. #Stocks #UK #NovoNordisk

Novo Nordisk flags. Courtesy of Novo Nordisk.

Novo Nordisk reported phase 2 results for UBT251 in type 2 diabetes, showing strong HbA1c and weight reduction after 24 weeks. Larger studies will still matter.

jcst2d.com/index.php/ne...

#Type2Diabetes #NovoNordisk #ClinicalTrials

Novo Nordisk headquarters. Courtesy of News Øresund - Johan Wessman - Licensed under CC BY 3.0. Photo link: https://www.flickr.com/photos/newsoresund/29190030262.

Novo Nordisk’s new Wegovy subscription program shows how serious the company is about direct-to-consumer and cash-pay obesity care, and how ready it is to compete with Lilly.

jcst2d.com/index.php/ne...

#Wegovy #NovoNordisk #ObesityCare

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly - Replaye Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and as much as $600 a year on the pill.

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
replaye.com/novo-nordisk...

#News #NovoNordisk #Wegovy #ObesityDrugs #Drugs #EliLilly

#NovoNordisk
www.youtube.com/watch?v=0k4i...

Mars CEO Named Novo Nordisk Board Observer Mars CEO appointed Novo Nordisk board observer on Mar 26, 2026; Novo Nordisk market cap topped $400bn in 2025, signalling cross-sector strategy with governance limits.

Mars CEO Named Novo Nordisk Board Observer: Mars CEO appointed Novo Nordisk board observer on Mar 26, 2026; Novo Nordisk market cap topped $400bn in 2025, signalling cross-sector strategy with governance limits. 👈 Read full analysis #Mars #NovoNordisk #CEO #BoardObserver #MarketCap

Pharmalittle: We're reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more The FDA approved a Denali medicine for Hunter syndrome, a notable decision as the agency has recently taken tougher stances on rare disease drugs

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more news.. statnews.com/pharmalot/20... #pharma #patents #obesity #340B #abortion #HIV #FDA #raredisease #Florida #NovoNordisk

Novo unveils first data for 'triple G' agonist in diabetes Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.

#NovoNordisk has reported the first clinical data with its triple G agonist for #diabetes, in China, as it starts an international trials programme.

pharmaphorum.com/news/novo-un...

ÚLTIMA HORA | Fin del monopolio de Ozempic: Expira la patente en 10 países y llegan los genéricos

https://youtu.be/FF5mOCg1cm4

#ultimahora #ozempic #farmacia #industrial #patentes #novonordisk #obesidad #semaglutida #sanidad #negociostv

Ozempic generics are arriving, but not yet in Europe Ozempic generics are about to enter some of the world’s biggest pharmaceutical markets as Novo Nordisk loses key patent protection for semaglutide in countries including India, China, Brazil, Turkey, South Africa and Canada. The shift could cut the cost of treatment sharply in places where the drug has remained out of reach for most patients, while leaving the USA and Europe on a different timeline. The Danish drugmaker built a global blockbuster around semaglutide, the active ingredient sold as Ozempic for type 2 diabetes and Wegovy for obesity. But from 21 March, manufacturers in several countries will be able to compete more directly with cheaper versions, opening a new phase in the market for GLP-1 medicines.

Ozempic generics are set to reach major markets, cutting semaglutide prices before Europe and the USA.

#novonordisk

Pharmalittle: We're reading about a Lilly weight loss trial, TrumpRx shortcomings, and more Diabetes patients taking an investigational drug from Eli Lilly saw significant reductions in their blood sugar and weight in a late-stage study

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a Lilly weight loss trial, TrumpRx shortcomings, and more news.. statnews.com/pharmalot/20... #pharma #weight #obesity #Trump #novonordisk #patents #Lilly #transparency #Maryland #advertising

#NovoNordisk is facing #generics of its #GLP1 drug in India, #Atrogi is testing a new #weightloss approach, and there's new data on #Structure's lead drug.

pharmaphorum.com/news/generic...

The weight-loss market has long been dominated by Eli Lilly and Novo Nordisk, but now a new player is entering the arena.

💊 If Sose Biotech’s drug gets approved, the market landscape could change dramatically!

#EliLilly #WeightLoss #Pharma #NovoNordisk #Biotech #MarketUpdate #Healthcare

Global healthcare company #NovoNordisk has completed a science-based materiality assessment and prioritization of its impacts on nature using #SBTN’s technical guidance, #validated by the Accountability Accelerator.

Find Novo Nordisk’s disclosure on SBTN’s Target Tracker: buff.ly/luLE3De

Novo rapped by FDA for not reporting drug adverse effects Novo Nordisk has been sent a warning letter from the FDA for violations of postmarketing adverse drug experience (PADE) regulations.

#NovoNordisk has been sent a #warningletter from the #FDA for a series of violations of postmarketing #adversedrugexperience (PADE) regulations, including failure to report #sideeffects among patients using its #GLP1 drugs for diabetes and weight loss.

pharmaphorum.com/news/novo-ra...

Original post on mastodo.neoliber.al

What is the cost of institutional rot?

Today, the FDA sent a warning letter to Novo Nordisk about systemic failures in their reporting of adverse events, specifically for Novo's blockbuster GLP1 medicine.

However... with RFK in charge of America's public health organs, we know RFK has a […]

⚠️ Two deaths. A suicide. And a reporting system that failed. How could this happen with a widely used medication? Click to uncover the full story 👉🏿 tinyurl.com/yx8b29p3
#MedicalSafety #GLP1 #WeightLossDrugs #HealthWatch #FDA #Health #Wellness #Ozempic #Wegovy #NovoNordisk #WeightLoss #Diabetes

Pharmalittle: We're reading about the FDA warning Novo Nordisk, Lilly investing in China, and more The Trump administration push for lower U.S. drug prices helped Astellas secure higher pricing for its new eye medicine in Japan

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about the FDA warning Novo Nordisk, Lilly investing in China, and more news.. statnews.com/pharmalot/20... #pharma #Trump #FDA #novonordisk #Ozempic #Wegovy #autism #weight #China #EliLilly

#trends today for 'weather forecast' 'surging oil' & 'novo nordisk'

Click/Tap below:

www.newsmason.com?query=%22wea...

www.newsmason.com?query=%22sur...

www.newsmason.com?query=%22nov...

#weatherforecast #surgingoil #novonordisk

Novo Nordisk is warned by the FDA for failing to report side effects It's the third time in recent weeks that the FDA has admonished Novo Nordisk for different practices.

Novo Nordisk is warned by the FDA for failing to report side effects.. (links to the letter & 483 are here).. statnews.com/pharmalot/20... #pharma #FDA #novonordisk #Ozempic #Wegovy #sideeffects #adverseevents #inspection

Months of legal wrangling between #NovoNordisk and telehealth company #HimsandHers has been set aside, as the two companies agree to work together once again on the sale of #GLP1agonists for #weightloss.

pharmaphorum.com/news/novo-pa...

Aandelen Hims & Hers stijgen met 50 procent na intrekking rechtszaak door Novo Nordisk Key takeaways Farmaceutgigant Novo Nordisk heeft haar rechtszaak tegen telezorgaanbieder Hims & Hers laten vallen. Volgens Nordisk verkocht Hims & Hers goedkopere- en niet-goedgekeurde kopieën van het populaire afslankmiddel Wegovy. Na overleg hebben de twee bedrijven een overeenkomst gesloten. Hims & Hers zal vanaf nu de medicijnen van Novo Nordisk op haar platform verkopen. Als […]

Aandelen Hims & Hers stijgen met 50 procent na intrekking rechtszaak door Novo Nordisk #HimsAndHers #NovoNordisk #Aandelen #Gezondheid #Telezorg

Actions Hims & Hers augmentent de 50 pour cent après le retrait de la plainte déposée par Novo Nordisk Principaux renseignements Le géant pharmaceutique Novo Nordisk a abandonné son procès contre le prestataire de télésanté Hims & Hers. Selon Nordisk, Hims vendait des copies moins chères et non approuvées du populaire médicament amaigrissant Wegovy. Après consultation, les deux entreprises ont conclu un accord. Hims & Hers vendra désormais les médicaments de Novo Nordisk sur […]

Actions Hims & Hers augmentent de 50 pour cent après le retrait de la plainte déposée par Novo Nordisk #HimsEtHers #NovoNordisk #Santé #Médicaments #Bourse